Total Valuation
Regencell Bioscience has a market cap or net worth of $3.52B. The enterprise value is $10.00T>.
Market Cap$3.52B
Enterprise Value$10.00T>
Share Statistics
Regencell Bioscience has 495,474,120 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding495,474,120
Owned by Insiders―
Owned by Institutions0.09%
Financial Efficiency
Regencell Bioscience’s return on equity (ROE) is -0.74 and return on invested capital (ROIC) is -69.75%.
Return on Equity (ROE)-0.74
Return on Assets (ROA)-0.62
Return on Invested Capital (ROIC)-69.75%
Return on Capital Employed (ROCE)-0.74
Revenue Per Employee0.00
Profits Per Employee-358.42K
Employee Count10
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Regencell Bioscience is ―. Regencell Bioscience’s PEG ratio is 137.27.
PE Ratio―
PS Ratio0.00
PB Ratio1.73K
Price to FCF-2.58K
Price to Operating Cash Flow-1.46K
PEG Ratio137.27
Income Statement
In the last 12 months, Regencell Bioscience had revenue of 0.00 and earned -3.58M in profits. Earnings per share was >-0.01.
Revenue0.00
Gross Profit-392.74K
Operating Income-3.77M
Pretax Income-3.58M
Net Income-3.58M
EBITDA-3.19M
Earnings Per Share (EPS)>-0.01
Cash Flow
In the last 12 months, operating cash flow was -2.59M and capital expenditures -2.00, giving a free cash flow of -2.59M billion.
Operating Cash Flow-2.59M
Free Cash Flow-2.59M
Free Cash Flow per Share>-0.01
Dividends & Yields
Regencell Bioscience pays an annual dividend of $0.22, resulting in a dividend yield of 318.47%
Dividend Per Share$0.22
Dividend Yield318.47%
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-1.03
52-Week Price Change-54.61%
50-Day Moving Average5.94
200-Day Moving Average18.94
Relative Strength Index (RSI)70.51
Average Volume (3m)165.51K
Important Dates
Regencell Bioscience upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Regencell Bioscience as a current ratio of 7.39, with Debt / Equity ratio of 31.68%
Current Ratio7.39
Quick Ratio7.39
Debt to Market Cap<0.01
Net Debt to EBITDA0.59
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Regencell Bioscience has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Regencell Bioscience EV to EBITDA ratio is -2.64K, with an EV/FCF ratio of -2.58K.
EV to Sales0.00
EV to EBITDA-2.64K
EV to Free Cash Flow-2.58K
EV to Operating Cash Flow-2.71K
Balance Sheet
Regencell Bioscience has $2.36M in cash and marketable securities with $386.30K in debt, giving a net cash position of $1.97M billion.
Cash & Marketable Securities$2.36M
Total Debt$386.30K
Net Cash$1.97M
Net Cash Per Share<$0.01
Tangible Book Value Per Share<$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Regencell Bioscience is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-227.78%